Back to search

Peptide record

TPDB08294

Epinecidin-8 Antibacterial Anticancer Toxicity standard

16 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB08294

Peptide_Name

Epinecidin-8

Activity

Antibacterial Anticancer Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF

Sequence_Type

standard

Has_Modification No

Description A 16-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Sequence

FIFHIIKGLFHAGKMI

FASTA

>TPDB08294|Antibacterial;Anticancer;Toxicity|length=16
FIFHIIKGLFHAGKMI

Formula C93H142N22O17S1

Absent Amino Acids RNDCEQPSTWYV

Common Amino Acids I

Mass 1872.35

PI 10.60

Basic Residues 4

Acidic Residues 0

Hydrophobic Residues 10

Net Charge +2

Boman Index -1.67

Hydrophobicity 1.181

Aliphatic Index 128.12

Half Life

Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 0

Absorbance 280nm 0.00

Polar Residues 0

number

Amino Acid Distribution

A: 1 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 2 H: 2 I: 4 L: 1 K: 2 M: 1 F: 3 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0

Length

Formula

C93H142N22O17S1

Mass

1872.35

10.60

Net Charge

Boman Index

-1.67

Hydrophobicity

1.181

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Epinephelus nebulosus

Evidence 1 Activity

Activity

Activity Raw

60 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Raw

50 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 3 Activity

Activity

Activity Raw

8 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 4 Activity

Activity

Activity Raw

10 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 5 Activity

Activity

Activity Raw

5 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 6 Activity

Activity

Activity Raw

75 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 7 Activity

Activity

Activity Raw

70 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 8 Activity

Activity

Activity Raw

5 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 9 Activity

Activity

Activity Raw

7 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 10 Activity

Activity

Activity Raw

10 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 11 Activity

Activity

Activity Raw

76 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 12 Activity

Activity

Activity Raw

70 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 13 Activity

Activity

Activity Raw

12 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 14 Activity

Activity

Activity Raw

4 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 15 Activity

Activity

Activity Raw

4 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 16 Activity

Activity

Activity Raw

90 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 17 Activity

Activity

Activity Raw

75 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 18 Activity

Activity

Activity Raw

8 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 19 Activity

Activity

Activity Raw

3 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 20 Activity

Activity

Activity Raw

3 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Cervical Cancer

Cell Line HeLa

Tissue Affected Cervix

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 21 Activity

Activity

Activity Raw

60 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 22 Activity

Activity

Activity Raw

50 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 23 Activity

Activity

Activity Raw

8 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 24 Activity

Activity

Activity Raw

10 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 25 Activity

Activity

Activity Raw

5 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 3-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 26 Activity

Activity

Activity Raw

75 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 27 Activity

Activity

Activity Raw

70 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 28 Activity

Activity

Activity Raw

5 %Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 29 Activity

Activity

Activity Raw

7 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 30 Activity

Activity

Activity Raw

10 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 6-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 31 Activity

Activity

Activity Raw

76 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 32 Activity

Activity

Activity Raw

70 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 33 Activity

Activity

Activity Raw

12 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 34 Activity

Activity

Activity Raw

4 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 35 Activity

Activity

Activity Raw

4 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 12-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 36 Activity

Activity

Activity Raw

90 % Cytotoxicity at 50 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 37 Activity

Activity

Activity Raw

75 % Cytotoxicity at 25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 38 Activity

Activity

Activity Raw

8 % Cytotoxicity at 12.5 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 39 Activity

Activity

Activity Raw

3 % Cytotoxicity at 6.25 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 40 Activity

Activity

Activity Raw

3 % Cytotoxicity at 3.125 mg/L

Detail Source Activity Anticancer

Target

Cancer Type Fibrosarcoma

Cell Line HT-1080

Tissue Affected Fibrous connective tissue

Assay & Model

Assay MTT/MTS assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP SATPdb

Source CancerPPD2

Year 2013

Evidence 41 Activity

Activity

Activity Endpoint 50% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 400 µg/mL

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

50% Hemolysis | 400 | µg/mL | target cell: Sheep erythrocytes

Target

Target Cell Sheep erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

Truncated antimicrobial peptides from marine organisms retain anticancer activity and antibacterial activity against multidrug-resistant Staphylococcus aureus. | Peptides | 2013

Evidence 42 Activity

Activity

Activity Endpoint % Hemolysis

Detail Source Activity Toxicity

Activity Measurement 0 %

Toxicity Type Hemolytic

Toxicity Raw

Hemolytic_activity: [Ref.23598079] 0% hemolysis at 50 mg/L , 10% hemolysis at 100 mg/L , 20% hemolysis at 200 mg/L , 50% hemolysis at 400 mg/L against sheep red blood cells

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Peptides. 2013 Jun 44:139-48. doi: 10.1016/j.peptides.2013.04.004.